Summary by Moomoo AI
Andrew Obenshain, an officer and director at Bluebird Bio, Inc., is set to sell 34,780 shares of the company's common stock. The transaction is scheduled for 09/30/2024, with the shares valued at an aggregate market value of $18,085.60. These shares were originally acquired on 08/02/2024, as vested restricted stock units under the company's equity plan, and were partly sold to cover withholding taxes. The securities were obtained from the issuer for services rendered. No other sales have been reported by Obenshain in the past three months. The notice for this planned transaction was filed on 10/01/2024, following the adoption of a plan or instruction given on 05/10/2023.
